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Abstract
Drug susceptibility testing (DST) is often needed in patients clinically failing tuberculosis (TB) therapy. Most studies of phenotypic direct
drug susceptibility tests, such as microscopic observation drug susceptibility (MODS) tests, have been performed in patients not receiving
TB treatment. The effect of ongoing TB treatment on the performance of MODS direct DST has not been previously explored, but patients
failing such therapy constitute an important target group. The aim of this study was to determine the performance of MODS direct
rifampicin and isoniazid DST in patients clinically failing ﬁrst-line TB treatment, and to compare MODS direct DST with indirect proportion
method DST. Sputa from 264 TB patients were cultured in parallel in Lowenstein–Jensen (LJ) and MODS assays; strains were tested for
rifampicin and isoniazid susceptibility by the proportion method at the national reference laboratory. Ninety-three samples were
culture-positive by LJ and MODS (concordance of 96%; kappa 0.92). With conventional MODS plate DST reading (performed on the same
day as the sample is classiﬁed as culture-positive), the isoniazid DST concordance was 96.8% (kappa 0.89), and the concordance for
rifampicin susceptibility testing was 92.6% (kappa 0.80). Reading of MODS DST plates 1 week after cultures had been determined to be
culture-positive improved overall performance marginally—the isoniazid DST concordance was 95.7% (kappa 0.85); and the rifampicin DST
concordance was 96.8% (kappa 0.91). Sensitivity for detection of multidrug-resistant TB was 95.8%. MODS testing provided reliable
rifampicin and isoniazid DST results for samples obtained from patients receiving TB therapy. A modiﬁed DST reading schedule for such
samples, with a ﬁnal reading 1 week after a MODS culture turns positive, marginally improves the concordance with reference DST.
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Introduction
Direct drug susceptibility testing (DST) is a potentially powerful
tool in the global battle against drug-resistant tuberculosis (TB).
By circumventing the delay inherent in primary culture and
strain isolation, and the additional workload and further delay
associated with the establishment of secondary cultures for
indirect DST, clinicians and their patients have access to this
important information in a clinically useful time frame [1–4].
Reservations about the validity of direct phenotypic DST for
Mycobacterium tuberculosis are based upon a perceived need to
control inoculum size. Overwhelming data obtained with several
different methodologies have now demonstrated that, whereas
this concern might be warranted for ethambutol and strepto-
mycin (which tend to not perform very well in direct DST),
direct DST shows high concordance with conventional indirect
reference methods for both rifampicin and isoniazid [1,5–7].
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The majority of published data on direct DST methodologies
come from diagnostic studies on patients who are not receiving
anti-TB therapy. For direct molecular resistance detection
methods, there is no reason why TB treatment should inﬂuence
test performance, and data can therefore be extrapolated to
treated patients. However, for phenotypic direct DST, which
depends on the growth of M. tuberculosis in the absence and
presence of carefully deﬁned assay drug concentrations, it is
biologically plausible that the presence of drug in the tissues and
respiratory secretions of a TB patient receiving treatment might
affect the performance of a direct drug susceptibility test.
Although the implementation of microscopic observation
drug susceptibility (MODS) testing in Peru is aimed at providing
pretreatment DST for all TB patients served by currently
available MODS laboratories, there is an important demand for
rapid DST in patients without baseline results who appear to be
failing therapy. In order to validate the use of MODS testing for
this indication, we undertook an evaluation in patients clinically
failing to respond to ﬁrst-line TB treatment. We compared the
rifampicin and isoniazid direct DST results obtained with
MODS testing with those obtained by the Peruvian national
mycobacteria reference laboratory by using the reference
standard, (indirect) proportion method testing, on agar.
Materials and Methods
Study setting, population, and recruitment
The study was performed in hospitals and health centres
across Lima and Lima-Callao between September 2008 and
December 2009. Patients failing to respond to ﬁrst-line TB
therapy (2RHZE6 4HR2), deﬁned as persistent symptoms
(weight loss, cough, fever, and night sweats) and/or sputum
smear non-conversion after 2 months of directly observed
treatment, are routinely referred to respiratory physicians for
evaluation, which usually includes conventional solid medium
culture of a sputum sample followed by indirect DST by the
proportion method on agar at the national TB reference
laboratory. During the study period, physicians referred such
patients to a member of the dedicated study team if a sputum
sample was to be taken and the patient indicated willingness to
participate in the study. Patients aged ≥18 years who agreed to
participate after reading the study information sheet and
discussing the study with the project nurse gave written
informed consent, responded to a brief structured question-
naire, and provided a sample of sputum.
Laboratory methods
Sputum samples were transported on the same day to the
research laboratory at Universidad Peruana Cayetano Heredia
(UPCH), where they were refrigerated until processing, usually
within 24 h. Each sample was decontaminated by the conven-
tional NaOH/N-acetyl-L-cysteine method, and auramine smear
microscopy was performed on the concentrated pellet. The
pellet was resuspended in supplemented Middlebrook 7H9
medium, and inoculated onto a Lowenstein–Jensen (LJ) slope
and into the MODS assay as described previously elsewhere [1]
(http://www.modsperu.org/MODS_user_guide.pdf).
MODS results were deﬁned as either positive (at least two
M. tuberculosis CFUs in each of the two drug-free control
wells) or not positive, which included negative (no CFUs in
either well) or indeterminate (M. tuberculosis CFUs observed
in only one well or fewer than two in both wells) or
contaminated cultures. For positive MODS cultures, the
results of rifampicin and isoniazid DST were deﬁned as
susceptible (no growth seen), resistant (at least two CFUs
seen) or indeterminate (only one CFU). The results of the
reference proportion DST method, deﬁned as susceptible or
resistant, were available to clinicians for patient care.
Data analysis
The primary outcome of interest was the concordance of
direct MODS DST results with those from the indirect
proportion DST method for rifampicin and isoniazid. We
constructed 2 9 2 tables separately for rifampicin and isoni-
azid, and percentage concordance and kappa values were
calculated (to determine percentage agreement beyond
chance).
Ethical review
The study protocol and informed consent form were reviewed
and approved by the Instituto Nacional de Salud (National
Institute of Health) and the National Tuberculosis Control
Programme (ESNPCT) of the Peruvian Ministry of Health, and
the ethics committee of UPCH, Lima, Peru.
Results
Culture
A single sputum sample was collected and processed for each
of 264 consecutive eligible patients failing ﬁrst-line TB therapy;
123 (46.6%) were auramine smear-negative, of whom 20
(16.3%) were culture-positive by either or both LJ and MODS
(Fig. 1), the remainder (n = 103) being culture-negative by
both MODS and LJ. Of the 141 smear-positive samples, 51
(36.2%) were culture-negative by both LJ and MODS. Of the
smear-positive samples, 43.7%, 76.9% and 93.5% of acid-fast
bacilli (AFB) 1+, AFB 2+ and AFB 3+ samples, respectively,
were culture-positive by either or both methods (Table 1).
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Concordance of MODS and LJ for TB detection in patients
receiving TB treatment
In total, 93 samples were culture-positive by both MODS and
LJ, 154 samples were not positive by either, and MODS and LJ
results differed for 17 samples—concordance by this measure
= 100 9 (93 + 154)/(93 + 154 + 17) = 93.6% (kappa 0.86).
However, among these 17 samples with discordant results,
only ten were positive by one culture method and negative by
the other; seven had positive or negative results by one
method, and were either contaminated or indeterminate by
the other (Table 2). After the application of stricter criteria to
limit the analysis to only those samples with two deﬁnitive (i.e.
positive or negative) results, concordance was 96.0%
(100 9 (93 + 149)/(93 + 149 + 10); kappa 0.92).
Rifampicin and isoniazid DST
Proportion method results were available for 94 strains: 92 of
the 93 that were culture-positive in LJ and MODS, plus two
that were culture-positive only in MODS, from which the
strain was sent for proportion method testing. By the
proportion method, 14 of 94 strains (14.9%) were susceptible
to both isoniazid and rifampicin, six of 94 (6.4%) were
isoniazid-monoresistant, two of 94 (2.1%) were rifampi-
cin-monoresistant, and 72 of 94 (76.6%) were resistant to
both isoniazid and rifampicin.
Conventional MODS DST well reading vs. the proportion
method
For diagnostic samples from patients not receiving TB
treatment, MODS DST wells are typically read and interpreted
on the same day that the MODS drug-free well cultures
become clearly positive. With this approach for samples with
deﬁnitive results, the concordance for isoniazid susceptibility
between MODS and the proportion method was 96.8%
(kappa 0.89) (Table 3), and the concordance for rifampicin
susceptibility was 92.6% (kappa 0.80) (Table 4).
Delayed ﬁnal MODS DST well reading vs. the proportion
method
Although wells were read and DST results classiﬁed as
described above, plates were retained and wells continued
to be read for up to 3 weeks after cultures became positive.
We analysed whether a modiﬁed (delayed) well interpretation
improved concordance, allowing growth in drug-containing
wells to be interpreted as resistant if it occurred within 7 or
14 days after TB growth was ﬁrst identiﬁed in drug-free wells
(and not only on the same day).
With this approach, the concordance for isoniazid sus-
ceptibility testing at 7 and 14 days after drug-free well
cultures turned positive was 95.7% and 95.7%, respectively
(kappa values of 0.85 and 0.85; Tables 5 and 6), and the
concordance for rifampicin susceptibility testing was 96.8%
and 96.8%, respectively (kappa values of 0.91 and 0.91;
Tables 7 and 8).
TABLE 1. 2 3 2 tables of microscopic observation drug
susceptibility (MODS) and Lowenstein–Jensen (LJ) culture
positivity of 141 auramine smear-positive samples according
to smear grading
AFB 1+
n = 71
AFB 2+
n = 39
AFB 3+
n = 31
LJ LJ LJ
+  +  + 
MODS
+ 23 2
MODS
+ 26 2
MODS
+ 29 0
 6 40  2 9  0 2
AFB, acid-fast bacilli.
For AFB 1+ MODS: sensitivity, 79.3%; speciﬁcity, 95.2%; positive predictive value
(PPV), 92.0%; negative predictive value (NPV), 87.0%.
For AFB 2+ MODS: sensitivity, 92.9%; speciﬁcity, 81.8%; PPV, 92.9%; NPV, 81.8%.
For AFB 3+ MODS: sensitivity, 100.0%; speciﬁcity, 100.0%; PPV, 100.0%; NPV,
100.0%.
FIG. 1. Smear and culture results for 264 samples from tuberculosis
patients apparently failing ﬁrst-line therapy. LJ, Lowenstein–Jensen;
MODS, microscopic observation drug susceptibility.
TABLE 2. 3 3 3 table of tuberculosis detection by Lowen-
stein–Jensen (LJ) and microscopic observation drug suscepti-
bility (MODS)
LJ
Positive Negative Indeterminate
MODS Positive 93 3 1a
Negative 7 149 1a
Indeterminate 6b 4b
MODS: sensitivity, 93.0%; speciﬁcity, 98.0%; positive predictive value, 96.9%;
negative predictive value, 95.5%.
aCulture contaminated.
bMycobacterial growth seen, but lower than the threshold of two CFUs in two
wells.
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The concordance for combined rifampicin/isoniazid DST
results when MODS readings were taken at 0, 7 and 14 days
after culture positivity is shown in Table 9; the sensitivity for
multidrug resistance (MDR) detection was 90.3%, 95.8% and
97.2%, respectively. Reading MODS DST results at day 7 after
culture positivity increased the accuracy of detection of
rifampicin resistance and MDR, at a minor cost in the
speciﬁcity of isoniazid resistance detection (isoniazid resis-
tance was slightly overestimated; see receiver operating
characteristic curve data in Fig. S1).
Discussion
The key ﬁnding of this study was that the results of MODS
isoniazid and rifampicin direct DST are as reliable for samples from patients receiving TB treatment as for samples
obtained before patients begin therapy. Importantly, the
sensitivities and speciﬁcities of MODS results for detection
of rifampicin monoresistance, isoniazid monoresistance and
MDR were comparable to those reported in previous
studies of MODS test performance with samples from
untreated patients [6], supporting the use of MODS testing
not only in those suspected of having TB and in newly
diagnosed TB patients prior to treatment initiation, but also
in patients failing treatment. Furthermore, clinicians and
laboratory staff can now be assured of the validity of MODS
DST when used for patients who have recently commenced
TABLE 4. Rifampicin drug susceptibility testing by direct
microscopic observation drug susceptibility (MODS) and
indirect proportion method testing for patients failing treat-
ment
Rifampicin
Proportion method
Susceptible Resistant
MODS
Susceptible 20 7
Resistant 0 67
For detection of rifampicin resistance with MODS testing: sensitivity, 90.5%;
speciﬁcity, 100.0%; positive predictive value, 100%; negative predictive value,
74.1%.
TABLE 3. Isoniazid drug susceptibility testing by direct
microscopic observation drug susceptibility (MODS) and
indirect proportion method testing for patients failing treat-
ment
Isoniazid
Proportion method
Susceptible Resistant
MODS
Susceptible 15 2
Resistant 1 76
Fordetectionof isoniazidresistancewithMODStesting: sensitivity, 97.4%; speciﬁcity,
93.8%; positive predictive value, 98.7%; negative predictive value, 88.2%.
TABLE 5. Isoniazid drug susceptibility testing by direct
microscopic observation drug susceptibility (MODS) and
indirect proportion method testing for patients failing treat-
ment, with reading 1 week after culture positivity
Isoniazid
Proportion method
Susceptible Resistant
MODS
Susceptible 14 2
Resistant 2 76
Fordetectionof isoniazidresistancewithMODStesting: sensitivity, 97.4%; speciﬁcity,
87.5%; positive predictive value, 97.4%; negative predictive value, 87.5%.
TABLE 6. Isoniazid drug susceptibility testing by direct
microscopic observation drug susceptibility (MODS) and
indirect proportion method testing for patients failing treat-
ment, with reading 2 weeks after culture positivity
Isoniazid
Proportion method
Susceptible Resistant
MODS
Susceptible 14 2
Resistant 2 76
For detection of isoniazid resistance with MODS: sensitivity, 97.4%; speciﬁcity,
87.5%; positive predictive value, 97.4%; negative predictive value, 87.5%.
TABLE 7. Rifampicin drug susceptibility testing by direct
microscopic observation drug susceptibility (MODS) and
indirect proportion method testing for patients failing treat-
ment, with reading 1 week after culture positivity
Rifampicin
Proportion method
Susceptible Resistant
MODS
Susceptible 20 3
Resistant 0 71
For detection of rifampicin resistance with MODS: sensitivity, 95.9%; speciﬁcity,
100.0%; positive predictive value, 100.0%; negative predictive value, 87.0%.
TABLE 8. Rifampicin drug susceptibility testing by direct
microscopic observation drug susceptibility (MODS) and
indirect proportion method testing for patients failing treat-
ment, with reading 2 weeks after culture positivity
Rifampicin
Proportion method
Susceptible Resistant
MODS
Susceptible 19 2
Resistant 1 72
For detection of rifampicin resistance with MODS: sensitivity, 97.3%; speciﬁcity,
95.0%; positive predictive value, 98.6%; negative predictive value, 90.5%.
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therapy without baseline DST, provided that they are still
culture-positive.
In MODS cultures of samples from untreated patients,
breakthrough growth is occasionally seen 1 or 2 weeks after
cultures are initially positive, but this does not correspond
with drug resistance; however, in this study of patients
receiving TB treatment, we observed that some late break-
through growth occurred in strains initially believed to be
monoresistant, so late growth was monitored. The sensitivity
of resistance detection was marginally improved when MODS
DST wells were re-read 1 week after the initial culture was
deemed to be positive; this contrasts with ﬁndings when
MODS testing is performed on samples from untreated
patients, when accuracy diminishes with delayed reading. This
might be because of a relative blunting of growth of
mycobacteria, owing to the presence of anti-TB drugs in the
sputum sample or exposure to TB drugs in vivo. Deferring the
ﬁnal MODS DST reading of drug-containing wells for an
additional week for samples from treated patients only may be
indicated when the source patient’s clinical history is known;
however, the utility of the modiﬁcation depends on the
availability of accurate clinical information. Moreover, the
marginal beneﬁt gained may not justify the additional com-
plexity of having different reading schedules for different
sample types. Laboratories might prefer to explore the
incremental beneﬁt of the delayed ﬁnal reading during the
MODS accreditation process [8].
An important strength of this study was the use of patients
from a crucial target group for DST, namely those TB patients
apparently failing ﬁrst-line therapy who had not undergone
baseline DST. MODS testing can accurately and quickly (usually
within 7–14 days) indicate whether more extended DST and
an interim switch to a standardized MDR treatment regimen is
needed. Data on the use of other non-commercial phenotypic
tests for direct DST in treated TB patients should also be
gathered, as these methodologies hold considerable promise
for widening the availability of affordable rifampicin and
isoniazid DST, a gateway to appropriate treatment for the
more than half a million patients with multidrug-resistant TB
around the globe [9].
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Figure S1a. Receiver operating characteristic (ROC) curve
indicating the effects of delayed (7 and 14 day) MODS DST
reading upon the sensitivity and speciﬁcity of detection of
isoniazid, rifampicin and combined isoniazid and rifampicin
resistance (MDR) in patients failing TB treatment.
Figure S1b. Detail of ROC curve from Fig. S1a.
TABLE 9. Combined rifampicin/isoniazid (RH) drug susceptibility testing (DST) and MODS DST results, with reading at 0
(conventional), 7 and 14 days after culture positivity; concordant results are highlighted in bold
Proportion method result
INH S
RIF S
INH R
RIF S
INH R
RIF R
INH S
RIF R
n = 14 n = 6 n = 72 n = 2
MODS result INH S R R S S R R S S R R S S R R S
RIF S S R R S S R R S S R R S S R R
Day 0 13 1 1 5 1 6 65 2
7 13 1 1 5 1 2 69 1 1
14 13 1 1 4 1 1 1 70 1 1
INH, isoniazid; R, resistant; RIF, rifampicin; S, susceptible.
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